癌症疫苗和溶瘤病毒在癌症患者中产生的副作用比其他全身治疗方法要低得多：一项比较分析。
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis.
作者信息
Schirrmacher Volker
机构信息
Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, Germany.
出版信息
Biomedicines. 2020 Mar 16;8(3):61. doi: 10.3390/biomedicines8030061.
Abstract
This review compares cytotoxic drugs, targeted therapies, and immunotherapies with regard to mechanisms and side effects. Targeted therapies relate to small molecule inhibitors. Immunotherapies include checkpoint inhibitory antibodies, chimeric antigen receptor (CAR) T-cells, cancer vaccines, and oncolytic viruses. All these therapeutic approaches fight systemic disease, be it micro-metastatic or metastatic. The analysis includes only studies with a proven therapeutic effect. A clear-cut difference is observed with regard to major adverse events (WHO grades 3-4). Such severe side effects are not observed with cancer vaccines/oncolytic viruses while they are seen with all the other systemic therapies. Reasons for this difference are discussed.
摘要
本综述比较了细胞毒性药物、靶向疗法和免疫疗法在作用机制和副作用方面的差异。靶向疗法涉及小分子抑制剂。免疫疗法包括检查点抑制抗体、嵌合抗原受体（CAR）T细胞、癌症疫苗和溶瘤病毒。所有这些治疗方法都用于对抗全身性疾病，无论是微转移还是转移阶段的疾病。分析仅纳入了具有已证实治疗效果的研究。在主要不良事件（世界卫生组织3 - 4级）方面观察到了明显差异。癌症疫苗/溶瘤病毒未观察到此类严重副作用，而在所有其他全身治疗中则可见到。本文讨论了造成这种差异的原因。
相似文献
1
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis.癌症疫苗和溶瘤病毒在癌症患者中产生的副作用比其他全身治疗方法要低得多：一项比较分析。
Biomedicines. 2020 Mar 16;8(3):61. doi: 10.3390/biomedicines8030061.
2
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.表达检查点抑制剂的溶瘤新城疫病毒作为一种放射性增强剂用于治疗鼠黑色素瘤。
EBioMedicine. 2019 Nov;49:96-105. doi: 10.1016/j.ebiom.2019.10.032. Epub 2019 Oct 29.
3
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.工程化新城疫病毒作为免疫检查点抑制剂和免疫细胞因子瘤内递送的溶瘤载体。
J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.01677-19.
4
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.溶瘤病毒与细胞疗法联合用于实体瘤治疗。
Front Immunol. 2018 Sep 21;9:2103. doi: 10.3389/fimmu.2018.02103. eCollection 2018.
5
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets.抗癌免疫疗法的进展：嵌合抗原受体T细胞疗法、免疫检查点抑制剂、树突状细胞疫苗和溶瘤病毒，以及新出现的细胞和分子靶点。
Cancers (Basel). 2020 Jul 7;12(7):1826. doi: 10.3390/cancers12071826.
6
Emerging Trends in Immunotherapy for Cancer.癌症免疫疗法的新趋势
Diseases. 2022 Sep 6;10(3):60. doi: 10.3390/diseases10030060.
7
Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.卵巢癌中的溶瘤病毒免疫疗法：超越腺病毒
Porto Biomed J. 2018 Jun 29;3(1):e7. doi: 10.1016/j.pbj.0000000000000007. eCollection 2018 Aug.
8
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.利用检查点抑制剂的肿瘤免疫疗法的力量。
Viruses. 2015 Nov 13;7(11):5889-901. doi: 10.3390/v7112914.
9
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.溶瘤腺病毒：在癌症与免疫系统的战斗中改变游戏规则的方法。
Expert Opin Biol Ther. 2019 May;19(5):443-455. doi: 10.1080/14712598.2019.1595582. Epub 2019 Mar 25.
10
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.癌症免疫疗法的当前模式：免疫调节抗体、嵌合抗原受体和疫苗。
Pharmacol Ther. 2017 Oct;178:31-47. doi: 10.1016/j.pharmthera.2017.03.008. Epub 2017 Mar 16.
引用本文的文献
1
CAR Cell-Derived Exosomes in Cancer Therapy: Biogenesis, Engineering Strategies and Antitumor Mechanisms.嵌合抗原受体（CAR）细胞衍生外泌体在癌症治疗中的作用：生物发生、工程策略及抗肿瘤机制
Int J Mol Sci. 2025 Aug 15;26(16):7890. doi: 10.3390/ijms26167890.
2
Glioblastoma: A Multidisciplinary Approach to Its Pathophysiology, Treatment, and Innovative Therapeutic Strategies.胶质母细胞瘤：关于其病理生理学、治疗及创新治疗策略的多学科方法
Biomedicines. 2025 Aug 2;13(8):1882. doi: 10.3390/biomedicines13081882.
3
Vaccines and Vaccination: Feature Papers.疫苗与预防接种：专题论文
Vaccines (Basel). 2025 Jul 1;13(7):720. doi: 10.3390/vaccines13070720.
4
Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis.溶瘤病毒疗法治疗恶性肿瘤患者的比较安全性和疗效：一项系统评价、荟萃分析和贝叶斯网络荟萃分析
EClinicalMedicine. 2025 Jul 19;86:103362. doi: 10.1016/j.eclinm.2025.103362. eCollection 2025 Aug.
5
New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.骨肉瘤免疫微环境与免疫治疗机制的新见解
Front Immunol. 2025 Jan 17;15:1539696. doi: 10.3389/fimmu.2024.1539696. eCollection 2024.
6
Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.溶瘤病毒与免疫疗法治疗葡萄膜黑色素瘤和视网膜母细胞瘤：现状与新进展
Biomedicines. 2025 Jan 6;13(1):108. doi: 10.3390/biomedicines13010108.
7
Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.溶瘤病毒治疗脑膜转移的挑战与策略。
J Transl Med. 2024 Nov 5;22(1):1000. doi: 10.1186/s12967-024-05794-4.
8
Strategies to overcome tumor microenvironment immunosuppressive effect on the functioning of CAR-T cells in high-grade glioma.克服肿瘤微环境对高级别胶质瘤中CAR-T细胞功能的免疫抑制作用的策略。
Ther Adv Med Oncol. 2024 Aug 15;16:17588359241266140. doi: 10.1177/17588359241266140. eCollection 2024.
9
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.超越 CAR-T：CAR-NK 细胞疗法在哮喘免疫治疗中的兴起。
J Transl Med. 2024 Aug 5;22(1):736. doi: 10.1186/s12967-024-05534-8.
10
Shifting cold to hot tumors by nanoparticle-loaded drugs and products.通过负载纳米颗粒的药物和产品将冷肿瘤转变为热肿瘤。
Clin Transl Oncol. 2025 Jan;27(1):42-69. doi: 10.1007/s12094-024-03577-3. Epub 2024 Jun 26.
本文引用的文献
1
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.免疫原性细胞死亡的定义、检测及解读的共识指南。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000337.
2
Intratumoral Immunotherapy-Update 2019.肿瘤内免疫治疗-2019 更新。
Oncologist. 2020 Mar;25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438. Epub 2019 Nov 29.
3
Toxicities of novel therapies for hematologic malignancies.血液系统恶性肿瘤新型治疗药物的毒性。
Expert Rev Hematol. 2020 Mar;13(3):241-257. doi: 10.1080/17474086.2020.1728249. Epub 2020 Feb 17.
4
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.突破治疗耐药性：溶瘤新城疫病毒改善癌症治疗的最新进展
Biomedicines. 2019 Aug 30;7(3):66. doi: 10.3390/biomedicines7030066.
5
Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.用于细胞免疫治疗的人类T细胞中具有记忆功能的诱导型基因开关
ACS Synth Biol. 2019 Aug 16;8(8):1744-1754. doi: 10.1021/acssynbio.8b00512. Epub 2019 Jul 16.
6
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics.嵌合抗原受体 T 细胞疗法的免疫原性。
BioDrugs. 2019 Jun;33(3):275-284. doi: 10.1007/s40259-019-00354-5.
7
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.talimogene laherparepvec：作用机制、临床疗效及安全性综述
Immunotherapy. 2019 Jun;11(8):705-723. doi: 10.2217/imt-2019-0033. Epub 2019 May 2.
8
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.癌症 DNA 疫苗：当前的临床前和临床进展及未来展望。
J Exp Clin Cancer Res. 2019 Apr 5;38(1):146. doi: 10.1186/s13046-019-1154-7.
9
Cancer Vaccines.癌症疫苗。
Hematol Oncol Clin North Am. 2019 Apr;33(2):199-214. doi: 10.1016/j.hoc.2018.12.001. Epub 2019 Jan 28.
10
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.评估纳武利尤单抗联合伊匹木单抗用于晚期黑色素瘤患者的两种剂量方案：来自 IIIb/IV 期 CheckMate 511 试验的结果。
J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.
Zotero 插件